Search the Newsreel

Replimune Group, Inc. (REPL) Investors Who Suffered Losses

Johnson Fistel, PLLP is investigating Replimune Group, Inc. (NASDAQ: REPL) after its shares fell approximately 30% following the FDA's release of briefing documents raising concerns about Replimune’s investigational RP1 therapy. The FDA staff concluded that the IGNYTE trial was not adequate and well-controlled, and …

REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug

Shares of Replimune Group Inc (REPL) dropped 38% after the FDA released documents questioning the approval of its experimental cancer drug RP1. This marks the company's third attempt for accelerated approval in combination with nivolumab for advanced melanoma, following prior rejections due to an …

Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff

The FDA has deemed Replimune's mid-stage study data for its lead drug RP1 as "not interpretable," challenging the company's application for accelerated approval in combination with Bristol-Myers Squibb Co.'s Opdivo for advanced melanoma. Concerns were raised regarding the efficacy assessment from the single-arm IGNYTE …

Simulations Plus, Inc. Revenue Breakdown – NASDAQ:SLP

Simulations Plus, Inc. (NASDAQ: SLP) generated a total revenue of $79.18 million USD last year. The Software segment was the top performer, contributing $45.83 million USD, an increase from $41.02 million USD in the prior year. The Americas region was the largest contributor to …

Replimune Stock Slides As Losses Deepen And Legal Risks Rise

Replimune Group Inc. (REPL) stock slid over 21% following clinical setbacks, deeper-than-expected losses, and a newly launched legal probe into alleged misstatements regarding its IGNYTE trial and RP1 program. The company reported a net loss of $3.38 per share, exceeding estimates, and faces a …

US FDA staff cast doubt on Replimune cancer drug’s benefit; shares slide

FDA staff reviewers have expressed doubts about the benefits of Replimune's skin cancer drug, RP1, citing flaws in the trial design that make it difficult to determine its effectiveness when used in combination with Bristol Myers Squibb's Opdivo. The FDA had previously declined approval …

Replimune (REPL) Slumps As Losses Mount And Legal Scrutiny Grows

Replimune Group Inc. (REPL) stock plunged by 18.66% amidst negative sentiment following its latest clinical trial outlook, wider-than-expected fiscal 2026 net losses, and a newly launched legal investigation into potential fiduciary duty breaches. Wedbush raised its price target from $6 to $9 but maintained …

PT Bank Pembangunan Daerah Banten (Perseroda) Tbk Class A Revenue Breakdown – IDX:BEKS

Maximus Inc (MMS) Cash Flow

This article provides a detailed historical cash flow statement for Maximus Inc (MMS), covering quarterly and annual periods for operating, investing, and financing activities. It presents financial data including net income, capital expenditures, debt issuance, and dividend payments, along with year-over-year percentage changes. The …

Yimutian Inc (YMT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Yimutian Inc (YMT), focusing on its PE, PB, and fair value. It appears to be a stub or an incomplete article, as it only presents general company information and basic stock metrics without detailed analysis. The content …

Yimutian Inc (YMT) Balance Sheet

This article presents the quarterly and annual balance sheets for Yimutian Inc. (YMT), offering key financial data such as cash and equivalents, total assets, liabilities, and shareholder equity. It also defines important balance sheet metrics and answers frequently asked questions about the company's financial …

Yimutian Inc (YMT) Income Statement

This article provides the quarterly and annual income statement for Yimutian Inc (YMT), detailing its financial performance. It includes key metrics such as total revenue, operating expenses, net income, and earnings per share for various fiscal periods. The article also features an FAQ section …

Replimune Group Inc (REPL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Replimune Group Inc (REPL), detailing its volatility, financial risk, and investment risk metrics. It includes data such as Beta vs S&P 500 index, VaR, maximum drawdown, daily returns (best and worst), Sharpe Ratio, and various volatility measures …

YMT|Yimutian Inc|Price:0.291|Chg%:-0.008

This article provides an overview of Yimutian Inc. (YMT) stock, including its current market price, key financial figures, performance trends, and technical indicators. Yimutian Inc. operates an agricultural Business-to-Business (B2B) platform aimed at digitalizing China's agricultural supply chain. The article details the company's business …

Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy

Shares of Replimune fell significantly after FDA reviewers raised concerns about the efficacy of its lead cancer therapy, RP1, for advanced melanoma. The FDA's briefing documents questioned the methodology of Replimune's IGNYTE study, suggesting that the tumor response and duration may have been overstated, …

Simulations Plus, Inc. $SLP Stock Position Boosted by First Light Asset Management LLC

First Light Asset Management LLC significantly increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 33.7% in the first quarter, now owning 13.03% of the company. Despite this, analyst sentiment has weakened, with a consensus "Reduce" rating and an average price target of $17.25. …

Health Check: It’s farewell, adieu as Imugene’s long-serving CEO calls it a day

Replimune Group Market Sentiment

This article provides an overview of the market sentiment for Replimune Group (REPL), highlighting analyst consensus, short interest, options flow, and recent insider activity. Key signals indicate a "Market Perform" consensus from analysts, a significant 49.9% short float that is trending downwards, and a …

REPL|Replimune Group Inc|Price:14.960|Chg%:-0.230

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

REPL|Replimune Group Inc|Price:12.060|Chg%:-0.800

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

PT Bank Pembangunan Daerah Jawa Timur Tbk Class B Revenue Breakdown – IDX:BJTM

Yimutian Inc. Revenue Breakdown – NASDAQ:YMT

This article provides a revenue breakdown for Yimutian Inc. (NASDAQ:YMT), highlighting that China was its largest contributing country to revenue in the last fiscal year, bringing in $19.57 million USD, a decrease from $22.42 million USD the prior year. The information is sourced from …

Imunon Inc (IMNN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Imunon Inc (IMNN), listing its major shareholders and institutional holdings. It shows that Armistice Capital LLC is the largest individual shareholder, and provides data on institutional ownership trends over several quarters, highlighting changes in shares held and …

TradingKey: Simulations Plus Inc (SLP) Income Statement Analysis

This article provides an in-depth look at the quarterly and annual income statements for Simulations Plus Inc (SLP) from TradingKey, detailing revenue, cost of revenue, operating expenses, and net income figures over several fiscal years. It offers a comprehensive financial summary, including year-over-year changes …

REPL|Replimune Group Inc|Price:9.700|Chg%:-0.760

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

Maximus Inc (MMS) Institutional Confidence

Maximus Inc (MMS) has an institutional shareholding score of 10.00, placing it first in the Professional & Commercial Services industry. Institutional investors hold 126.59% of shares, a 17.86% increase quarter-over-quarter. Chuck Royce is the largest institutional shareholder with 0.70% of outstanding shares.

Imunon, Inc. Revenue Breakdown – NASDAQ:IMNN

The article "Imunon, Inc. Revenue Breakdown – NASDAQ:IMNN" is a financial overview of Imunon, Inc. (IMNN) on TradingView. It provides access to the company's financials, including statements, statistics, dividends, earnings, and segment performance. The page appears to be a portal for investors to research …

IMNN|Imunon Inc|Price:1.510|Chg%:-0.150

Imunon Inc. (IMNN) is a clinical-stage biotechnology company focused on treatments utilizing the body's natural mechanisms, distinct from conventional therapies. The company is developing non-viral DNA technology across two modalities: TheraPlas for solid tumors and PlaCCine for viral antigens. Their lead program, IMNN-001, an …

OPTU|Altice USA Ord Shs Class A|Price:0.806|Chg%:-0.049

Altice USA Ord Shs Class A (OPTU) is currently trading at $0.806, representing a -5.65% change from its previous close. The company's market capitalization is $383.98 million. Analysts have a "Hold" rating for OPTU with a target price of $1.27, suggesting a 41.11% upside.

Imunon Inc (IMNN) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Imunon Inc (IMNN), providing a score of 6.70 which ranks it 222 out of 386 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low operating efficiency. Key financial metrics such …

TradingKey

This article provides a detailed cash flow statement for Yimutian Inc. (YMT), including operating, investing, and financing cash flows, along with related frequently asked questions. It shows the company's financial movements for FY2025Q1, indicating negative operating and investing cash flows, and also details free …

Maximus Inc (MMS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts and stock split events for Maximus Inc (MMS). It details quarterly cash dividends, including their gross amounts, record dates, payment dates, and ex-dividend dates, spanning from 2024 through 2026. The data indicates that Maximus Inc …

Maximus Inc (MMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Maximus Inc (MMS), detailing its financial performance by region. As of March 4, 2025, the company generated $3.87 billion (83.51%) from the United States, $410.59 million (8.87%) from the United Kingdom, $180.00 million (3.89%) from the Rest …

MAXIMUS, Inc. Revenue Breakdown – LS:907462

MAXIMUS, Inc. generated 4.63 billion EUR in revenue last year, with its United States Federal Services segment contributing 2.61 billion EUR. The U.S. was the largest regional contributor, accounting for 4.12 billion EUR of the total revenue. This article details the top segments and …

How Maximus’ Higher Dividend Yield and Low Payout Ratio Could Shape MMS Investors’ Income Outlook

Maximus, Inc. recently announced a 10% increase in its annualized dividend, resulting in a 2.29% yield, which surpasses its industry and the S&P 500, while maintaining a low 17% payout ratio. This move, coupled with projected earnings growth for 2026 and sustained revenue guidance, …

MMS|Maximus Inc|Price:61.297|Chg%:+1.627

This article provides a comprehensive stock analysis of Maximus Inc (MMS) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation. The report notes high institutional ownership and a "Buy" rating from multiple analysts with a target price of $105.00. Despite good …